Here’s what you should know:
1. Exact Sciences increased sales 158 percent, year-over-year.
2. Exact Sciences completed 161,000 Cologuard tests in the third quarter. Test volume grew 136 percent, year-over-year.
3. Cologuard earned approximately $451 per test.
4. Exact Sciences CEO Kevin Conroy said in a release, “A growing number of patients and physicians are demanding Cologuard. Through our direct-to-consumer television and marketing campaign and our national sales force, we are reaching a larger percentage of the 80 million people eligible to be screened with Cologuard.”
5. Concerning rest-of-year outlooks, Exact Sciences expects revenues between $254 million and $257 million for 2017. Exact Sciences estimates up to 177,000 more tests will be completed in the fourth quarter of 2017.
More articles on gastroenterology:
GI leader to know: Dr. Ravi Mallavarapu of Cedar Valley Gastroenterology
The VA has a high HCV treatment rate — 7 insights into why they’re so successful
5 latest findings on gut microbiome & human development
